Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
Zacks.com on MSN3d
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...
Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market experienced mixed results on Tuesday. The Dow Jones index climbed over 220 points to 42,518.28, while ...
Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly’s drag
Asian shares are mixed after gains for oil and gas producers helped offset drops for Nvidia and other Big Tech companies on ...
Wall Street mostly rises after encouraging inflation data despite Lilly’s drag
Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...
S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens
The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's ...
Stock market today: Dow pops, Nasdaq slips as focus turns to CPI inflation report
Investors are weighing what a reported gradual rollout of Trump tariff hikes could mean for inflation and the Fed.
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...